Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 7/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.33 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.32 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.30 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.30 |
| ▸ | NRAS | P01111 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17304012 | 0.84 | FLT3 (0.39) | HRH3FLT3KCNN2KCNN3LMNA | |
| SCHEMBL19171756 | 0.83 | CCNT1 (0.35) | CCNT1CDK9KCNN2KCNN3LMNA | |
| SCHEMBL17300778 | 0.82 | HRH3 (0.34) | HRH3FLT3CCNT1CDK9MAP3K12 | |
| SCHEMBL15829873 | 0.80 | HRH3 (0.39) | HRH3FLT3KCNN2KCNN3LMNA | |
| SCHEMBL17345633 | 0.74 | MEN1 (0.49) | HRH3CCNT1CDK9MEN1KMT2A | |
| SCHEMBL12871107 | 0.72 | POLB (0.39) | LMNAMEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL15829872 | 0.72 | HRH3 (0.39) | HRH3FLT3CCNT1CDK9KCNN2 | |
| SCHEMBL15830005 | 0.72 | HRH3 (0.39) | HRH3FLT3CCNT1CDK9KCNN2 | |
| SCHEMBL15833955 | 0.72 | HRH3 (0.39) | HRH3FLT3KCNN2KCNN3LMNA | |
| SCHEMBL17303779 | 0.71 | MALT1 (0.41) | HRH3FLT3KCNN2KCNN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935247-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-2935243-B1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | EPIZYME INC (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-9604930-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150344434-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| WO-2014100730-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100719-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100734-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HRH3 1072/4885FLT3 791/4885CCNT1 2515/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HRH3 629/4885FLT3 1014/4885CCNT1 2718/4885 |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | HRH3 1208/4885FLT3 307/4885CCNT1 1352/4885 |
| US-20150344434-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HRH3 683/4885FLT3 1034/4885CCNT1 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.